ArticleDiscover oncology2026
Integrating machine learning and spatiotemporal transcriptomics to build a diagnostic model for osteosarcoma metastasis and to decipher the role of necroptosis genes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo develop a diagnostic model for osteosarcoma metastasis and elucidate the spatiotemporal role of necroptosis genes.
methodsMulti-omics data (TCGA/GEO, single‑cell, spatial transcriptomics) were integrated using 113 machine learning algorithms. Core genes were identified, followed by prognostic analysis, drug screening, molecular docking, and spatiotemporal mapping. Experimental validation included RT‑qPCR in four osteosarcoma cell lines and independent transcriptomic sequencing.
resultsThe glmBoost+Ridge model selected seven core genes (e.g., FOS, MYC), achieving AUCs of 0.861 (training) and 0.873 (validation). A combined risk score predicted prognosis (AUC = 0.790). Pseudotime analysis showed MYC up‑regulation and TNFRSF21 loss during metastasis; spatially, MYC localized to invasive fronts while TNFRSF21‑deficient regions formed immune‑exempt zones. Experimental data confirmed MYC overexpression/TNFRSF21 underexpression in metastatic cells and revealed a strong negative correlation (r = -0.931). Calcitriol and Sulindac were identified as potential therapeutic candidates.
conclusionThis study provides a diagnostic model for osteosarcoma metastasis and proposes that MYC/TNFRSF21 drive metastasis via a "necroptosis‑immune exemption" axis, suggesting new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.